Current investments
We do not have any companies open for investments at the moment. Sign up to receive an email once something new is coming up.
Completed investments
Pharmnovo AB
PharmNovo develops a novel drug for nerve pain, where there is a high, unmet need for effective and safe treatments. The candidate PN6047 shows effective pain relief in animal models, without the negative side effects associated with existing drugs.
Capitainer AB
Capitainer offers a more convenient and cost-efficient way to take blood samples. The company’s products are designed for home sampling and deliver an exact amount of blood, which is essential to get accurate results.
NEOGAP Therapeutics AB
NEOGAP has a unique approach to train the patient’s immune system to target tumour-specific mutations, so called neoantigens to eradicate the cancer. The treatment has the potential to kill the cancer cells while leaving healthy cells untouched, which significantly reduces the risk of side effects.
Exits
Inhalation Sciences
Inhalation Science’s technology is used by leading players in the chemical and pharmaceutical sectors to study how airborne particles affect the human body.
Read more
Lipigon Pharmaceuticals
Lipigon develops orphan drugs for illnesses due to disorders in how the body handles fat. The company’s major program, Lipsense, focuses on the illness, HoFH, where there is, today, no sufficient treatment.
Read more